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Objectives The aim of this study was to evaluate whether cardiac biomarkers, tissue velocity (TVI) and strain imaging, and
cardiac magnetic resonance imaging can predict early left ventricular (LV) dysfunction in human epidermal
growth factor receptor II–positive breast cancer patients treated with trastuzumab in the adjuvant setting.
Background Early indexes of LV systolic dysfunction with noninvasive cardiac imaging would be useful for addressing the car-
diac safety profile of trastuzumab, potentially avoiding the detrimental effects of heart failure.
Methods We used cardiac biomarkers, TVI and strain imaging, and cardiac magnetic resonance imaging to detect pre-clinical
changes in LV systolic function, before conventional changes in left ventricular ejection fraction (LVEF) in human epi-
dermal growth factor receptor II–positive breast cancer patients treated with trastuzumab in the adjuvant setting.
Results Of 42 patients (mean age 47  9 years) prospectively followed between 2007 and 2009, 10 (25%) developed
trastuzumab-mediated cardiomyopathy (CM). Troponin T, C-reactive protein, and brain natriuretic peptide did not
change over time. Within 3 months of adjuvant therapy with trastuzumab, there was a significant difference in the
lateral S= between the normal cohort and the CM group (9.1  1.6 cm/s and 6.4  0.6 cm/s, respectively, p 
0.05). Similarly, the peak global longitudinal and radial strain decreased as early as 3 months in the trastuzumab-
mediated cardiotoxicity group. As compared with both global longitudinal and radial strain, only S= was able to iden-
tify all 10 patients who developed trastuzumab-mediated CM. The LVEF subsequently decreased at 6 months of
follow-up in all 10 patients, necessitating discontinuation of the drug. All 10 patients demonstrated delayed enhance-
ment of the lateral wall of the LV within the mid-myocardial portion, consistent with trastuzumab-induced CM.
Conclusions Both TVI and strain imaging were able to detect pre-clinical changes in LV systolic function, before conventional
changes in LVEF, in patients receiving trastuzumab in the adjuvant setting. (J Am Coll Cardiol 2011;57:
2263–70) © 2011 by the American College of Cardiology Foundation
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Chemotherapy-Induced Cardiac Dysfunction May 31, 2011:2263–70Breast cancer is the second lead-
ing cause of death due to cancer
in women in Canada (1). The
treatment for breast cancer is in-
dividualized to each patient and
involves a combination of surgery,
chemotherapy, and radiation ther-
apy. Typically, 2 to 3 chemother-
apeutic agents are given with each
treatment cycle, with the most
common regimen including a
combination of 5-fluorouracil, an-
thracyclines (epirubicin or doxoru-
bicin), and cyclophosphamide
(FEC) (2).
See page 2271
An increased understanding of
the biology of breast cancer has
lead to the identification of novel
therapeutic targets. Among these
targets, human epidermal growth
factor receptor II (HER-2), a
member of the epidermal growth
factor receptor family, is detected
as overexpressed in 25% to 30% of
all breast cancers (3). Amplifica-
tion of HER-2 confers aggressive
behavioral traits on breast cancer
cells, including enhanced growth
and proliferation, increased invasive-
ness, and metastatic capability (3).
Trastuzumab is a humanized
monoclonal antibody that targets
the extracellular portion of the
HER-2 membrane protein, which
is approved for the treatment of
patients with HER-2 positive
breast cancer, both in the adjuvant
and metastatic settings (4–9). De-
spite its rapid adoption in the management of breast cancer,
trastuzumab is known to potentiate the cardiotoxic effects of
anthracyclines. The use of trastuzumab is associated with a 5%
to 10% risk of asymptomatic cardiac dysfunction and a 1% risk
of symptomatic congestive heart failure (CHF) in clinical trials
(7–9). Recent studies have shown a higher risk of nearly 1 in 4
breast cancer patients developing trastuzumab-mediated car-
diac dysfunction, reversible in a majority of cases (10,11). Early
subclinical detection of trastuzumab-induced cardiotoxicity
would be clinically useful in this patient population.
Cardiac biomarkers are protein molecules that are widely
used in the early detection of heart failure. Serum levels of
troponin T (TnT), C-reactive protein (CRP), and brain
natriuretic peptide (BNP) have been shown to be sensitive
Abbreviations
and Acronyms
a=  late diastolic annular
velocity of the lateral wall
AC  adriamycin and
cyclophosphamide
BNP  brain natriuretic
peptide
CHF  congestive
heart failure
CM  cardiomyopathy
CRP  C-reactive protein
CV  coefficient of
variation
e=  early diastolic annular
velocity of the lateral
left ventricular wall
FEC  fluorouracil,
epirubicin, and
cyclophosphamide
LGE  late gadolinium
enhancement
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
MRI  magnetic resonance
imaging
NPV  negative
predictive value
PPV  positive
predictive value
S=  systolic annular
velocity of the lateral
left ventricular wall
TnT  troponin T
TTE  transthoracic
echocardiography
TVI  tissue velocity
imagingmarkers of left ventricular (LV) dysfunction and powerfulmarkers of morbidity and mortality in the heart failure
setting (12–14). All 3 cardiac biomarkers have been
evaluated after anthracycline treatment (15,16). How-
ever, their ability to predict early cardiac dysfunction
remains unknown in the clinical setting of trastuzumab-
mediated cardiotoxicity.
One of the current methods of monitoring LV function
in patients receiving adjuvant trastuzumab therapy is deter-
mination of left ventricular ejection fraction (LVEF) with
serial transthoracic echocardiography (TTE). However, as-
sessment of LVEF is dependent on hemodynamic condi-
tions and fails to detect early subtle alterations in LV systolic
function that occurs in the later stages of chronic disease.
Tissue velocity imaging (TVI) and strain imaging are
sensitive, noninvasive echocardiographic techniques that
allow for the early detection of LV systolic dysfunction,
before a decrease in conventional LVEF (17). Tissue veloc-
ity imaging has been validated in murine models of
chemotherapy-induced cardiac dysfunction (18,19) and re-
cently evaluated in the clinical setting of doxorubicin and
trastuzumab-induced cardiac dysfunction (20,21). However,
early detection of cardiac injury with cardiac biomarkers and
TVI in the clinical setting of adjuvant trastuzumab therapy
has yet to be investigated.
In addition to TTE, cardiac magnetic resonance imaging
(MRI) might be used for the noninvasive assessment of LV
volumes and LVEF in the breast cancer setting (22,23).
Improvements in both spatial and temporal resolution have
made cardiac MRI the gold standard for the noninvasive
assessment of LV systolic function (24). Although delayed
enhancement imaging with cardiac MRI might identify
patients with trastuzumab-mediated cardiotoxicity (22,23),
its use for the early prediction of LV dysfunction remains
unexplored.
Thus, we sought to evaluate whether cardiac biomarkers,
TVI and strain imaging, and cardiac MRI can predict early
LV dysfunction in HER-2 positive breast cancer patients
treated with trastuzumab in the adjuvant setting.
Methods
From January 2007 to January 2009 inclusive, 42 consecu-
tive female patients were prospectively identified to have
received trastuzumab in the adjuvant setting of HER-2
overexpressing breast cancer. After the anthracycline-based
chemotherapy regimen, the patients received a loading dose
of 8 mg/kg of trastuzumab followed by a maintenance dose
of 6 mg/kg every 3 weeks for 1 year. Trastuzumab-mediated
cardiomyopathy (CM) was defined as a decline in LVEF of
at least 10% below 55%, with accompanying signs or
symptoms of CHF, necessitating discontinuation of the
drug (6–8) The study protocol was approved by the local
institutional review board.
In total, the patient population was evaluated at 6 separate
time points: 1) before the initiation of anthracycline-based
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(3 weeks after the final cycle of chemotherapy); 3) 3 months; 4)
6 months; 5) 9 months; and 6) 12 months after the initiation
of trastuzumab. At each visit, blood was drawn to measure
TnT, CRP, and BNP, and a standard TTE was performed.
The patients underwent a cardiac MRI at baseline and 12
months after the initiation of trastuzumab treatment.
Troponin T, CRP, and BNP were evaluated at 6 separate
time points. Quantitative determinations of TnT levels were
performed with a third-generation Roche Elecsys assay
(Roche Diagnostics, Inc., Indianapolis, Indiana). The CRP
levels were measured with the Immage 800 (Beckman
Coulter, Brea, California) antigen-antibody precipitant rate
reaction. The N-terminal pro-BNP levels were measured
with an electrochemiluminescence sandwich immunoassay
(Elecsys ProBNP, Roche Diagnostics) with the Roche 2010
system.
Serial TTE with TVI was performed on a GE Vivid 7
platform (General Electric, Milwaukee, Wisconsin). For
2-dimensional TTE, parasternal and apical views were
obtained with a standard echocardiograph (GE Vivid 7,
General Electric) with a multifrequency transducer. The
LV cavity dimensions and LVEF were determined from
2-dimensional images according to established criteria,
including the modified biplane Simpson’s method (25).
Tissue Doppler-derived indexes were recorded at the base
of the lateral mitral annuli to determine longitudinal endo-
cardial velocities. These indexes included systolic (S=), early
diastolic (e=), and late diastolic (a=) velocities. Doppler-
independent strain was also assessed with offline semi-
automated speckle tracking techniques in the parasternal
and apical views to determine both global longitudinal and
radial strain (EchoPac, Version 7.01, General Electric) (17).
Serial cardiac MRI was performed with a 1.5-T scanner
(Avanto, Siemens, Erlangen, Germany) at baseline and 12
months of follow-up. Transverse images were acquired with
an inversion recovery prepared dark blood HASTE se-
quence (repetition time [TR] 600 ms, echo time [TE] 26
ms, 6 mm slice thickness, 1.8 mm interslice gap, matrix
256  104). Cine bright-blood images in the 4- and
2-chamber long-axis planes were performed with a breath-
hold balanced steady-state free precession sequence (true
fast imaging with steady-state precession, TR 42 ms, TE
1.2 ms, fractional anisotropy 70°, 6 mm slice thickness,
matrix 192  174). Cine breath-hold balanced steady-state
free precession short-axis images then encompassed the
entire LV from the base to the apex (stack of 10 sequential
short-axis slices; TR 64 ms, TE 1 ms, fractional anisotropy
80°, 8 mm slice thickness, 1.6 mm interslice gap, matrix
192  132) to obtain an LVEF. To evaluate for myocardial
edema, dark blood T2-weighted turbo spin echo short-axis
images were obtained (TR 1,800 to 2,100 ms, TE 74 ms, 8
mm slice thickness, 4 mm interslice gap, matrix 256 175).
Late gadolinium enhancement (LGE) images were ob-
tained after 10 min of 0.2 mmol/kg injection of gadolinium
(Gd-DTPA, Magnevist, Schering, Germany) with a T1-weighted inversion recovery-prepared multislice true fast
imaging with steady-state precession sequence with magni-
tude and phase-sensitive reconstruction. Images were ac-
quired sequentially in the short axis, followed by horizontal
and vertical long-axis images (TR 700 ms, TE 1.0 ms,
fractional anisotropy 40°, 8 mm slice thickness, 1.6 mm
interslice gap, matrix 192  144). To quantify the myocar-
dial mass of the LGE, the endocardial and epicardial
borders of the short-axis view of the LV were manually
traced. The computer-assisted detection algorithm defined
LGE as any region with a signal intensity 2 SD above a
reference remote myocardial region. The LGE mass was
expressed as a percentage of the LV mass. Quantitative
analysis was performed with dedicated computer software
(CMR44, Release 3.0.0, Circle Cardiovascular Imaging,
Calgary, Alberta, Canada).
The data are summarized as mean  SD or n (%). Paired
Student t tests were used to compare continuous variables.
Chi-square and Fisher exact tests were applied to compare
categorical variables. Comparison of variables between the
normal population and trastuzumab-induced CM at the
same time point were done with the Mann-Whitney U test.
Comparison of variables within each group versus baseline
was performed with repeated measures analysis of variance
and Dunnett’s test. A significant decrease in LVEF was
defined as an ejection fraction drop 10%, as compared
with the baseline echocardiogram. A significant decrease in
TVI or strain was defined as a decrease exceeding the
receiver-operator characteristic curve defined cutoff value of
the relevant parameter assessed at the first available echo-
cardiogram. Due to the small sample size of the CM group,
the difference between baseline and 3-month measurements
for S=, longitudinal strain, and radial strain were used as
input variables. This allowed for development of binormal
receiver-operator characteristic curves and the calculation of
cutoff values based on optimal choices for sensitivity and
specificity from the curves. Receiver-operator characteristic
curve analysis was applied to determine cutoff values, sen-
sitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) for S=, longitudinal strain,
and radial strain measurements. Sensitivity, specificity,
PPV, and NPV were calculated with Bayes’ Theorem,
assuming a 25% prevalence of CM patients in the study
population (26). Intra-observer variability and inter-
observer variability for TVI and strain were measured by the
intraclass correlation coefficient and by the coefficient of
variation (CV) with the root-mean-square method. A
p value 0.05 was considered statistically significant. The
Statistical Analysis System (version 8.01, SAS Institute,
Cary, North Carolina) was used to perform the analysis.
Results
The study population included 42 patients (mean age 47 
9 years) with an average body mass index of 25  7 kg/m2.
Of the entire population, 10 (24%) women developed
d
l
g
c
c
T
p
r
(
c
c
m
t
c
a
l
s
c
m
b
W
a
p
L
0
i
o
a
e
a
b
m
s
c
d
t
(
1
a
P
(
c
i
t
a
d
T

a
v
v
i
d
n

2266 Fallah-Rad et al. JACC Vol. 57, No. 22, 2011
Chemotherapy-Induced Cardiac Dysfunction May 31, 2011:2263–70trastuzumab-induced CM, defined as a decline in LVEF of
at least 10% below 55%, with accompanying signs or symp-
toms of CHF, necessitating discontinuation of the drug. The
prevalence of underlying cardiovascular risk factors was low in
this patient population, as shown in Table 1. There was no
ifference in the location and size of breast cancer, axillary
ymph node involvement, or radiation use between the 2
roups (Table 1). The majority of patients (88%) received 6
ycles of FEC 100, whereas the remaining 12% received 4
ycles of adriamycin and cyclophosphamide (AC) therapy.
he median delivered dose intensity, as percentage of the
rotocol-assigned dose, was 100% for both FEC and AC,
espectively. The maximum cumulative dose for epirubicin
600 mg/m2) and adriamycin (240 mg/m2) was not ex-
eeded in any patient and did not differ between the normal
ohort and those patients who developed trastuzumab-
ediated CM. All patients received adjuvant therapy with
rastuzumab within 3  1 months of completing the
hemotherapy regimen.
At baseline, cardiac biomarkers—including TnT, CRP,
nd BNP—were within normal limits for the entire popu-
ation (Table 2). At 12 months of follow-up, there was no
ignificant change in biomarker levels between the normal
ohort and those patients who developed trastuzumab-
ediated CM.
The mean LVEF for the total population was 63 4% at
aseline with conventional echocardiography (Table 3).
ithin 6 months of treatment with trastuzumab, there was
significant difference between the normal cohort and those
atients who developed LV systolic dysfunction, with
VEF values of 64  4% and 42  9%, respectively (p 
Baseline Characteristics of Total PopulationTable 1 Baseline Characteristics of Total Population
Characteristics
Normal
(n  32)
CM
(n  10)
Total Population
(n  42) p Value
Age (yrs) 46 8 47 10 47 9 0.48
BMI (kg/m2) 26 5 25 6 25 7 0.90
CV risk factors
Hypertension 4 (13) 1 (10) 5 (12) 1.00
Diabetes 4 (13) 2 (20) 6 (14) 0.62
Hyperlipidemia 12 (38) 3 (30) 15 (36) 1.00
Smoking history 2 (6) 2 (20) 7 (17) 0.24
Family history of CAD 4 (13) 3 (30) 12 (29) 0.33
Location of Ca
Right 19 (59) 6 (60) 25 (60) 1.00
Left 11 (34) 4 (40) 15 (39.5) 1.00
Bilateral 2 (2.6) 0 (0) 2 (2.0) 1.00
Size of Ca (cm) 3.0 2.0 3.2 1.4 3.1 1.7 0.83
Radiation 31 (97) 10 (100) 41 (98) 1.00
Lymph node  19 (58) 5 (50) 24 (57) 0.72
Chemotherapy
FEC 29 (91) 8 (80) 37 (88) 0.58
AC 3 (7) 2 (20) 5 (12) 0.58
n  42. Values are mean  SD or n (%). p values were calculated by Student t test for difference
n means between normal and cardiomyopathy (CM) groups and the Fisher exact test for
ifferences in proportions.w
AC  adriamycin, cyclophosphamide; BMI  body mass index; Ca  cancer; CAD  coronary
artery disease; CV  cardiovascular; FEC  fluorouracil, epirubicin, cyclophosphamide..05). In women with CM, there was a progressive decline
n LVEF to 39  5% at 9 months, despite discontinuation
f trastuzumab and initiation of heart failure therapy with
ngiotensin-converting enzyme inhibitors and beta block-
rs. The LVEF began to recover in the majority of patients
t 12 months with a mean LVEF of 49  4% (Table 3).
Tissue velocity imaging and strain values were similar
etween both groups at baseline (Table 3). Within 3
onths of adjuvant therapy with trastuzumab, there was a
ignificant difference in the lateral S= between the normal
ohort and those patients who developed LV systolic
ysfunction (9.1  1.6 cm/s and 6.4  0.6 cm/s, respec-
ively, p  0.05). With a cutoff value of 0.60 cm/s
difference between baseline and 3-month values for S=), all
0 patients who developed trastuzumab-mediated CM were
bove this threshold (Table 4). The sensitivity, specificity,
PV, and NPV were 93%, 99%, 96%, and 98%, respectively
Table 4). There were no false positives in the normal
ohort (n  32). The LVEF subsequently decreased 10%
n the CM group at 6 months and continued to decline up
o 9 months of follow-up. There was no difference in e= and
= between the normal cohort versus CM at each time point.
Similarly, the peak global longitudinal and radial strain
ecreased as early as 3 months in the CM group (Table 3).
he peak global longitudinal strain decreased from
19.8  1.8% at baseline to 16.4  1.1% at 3 months
nd continued to decline up to 9 months. With a cutoff
alue of 2.00% (difference between baseline and 3-month
alues for peak longitudinal strain), 7 of 10 CM patients
Summary of Serial Cardiac Biomarkers of PatientsWith and Without Tr stuzumab-Mediated CM inEn ire Population
Table 2
ummary of Seri l Car i c Biomarkers of Patients
With and Without Trastuzumab-Mediated CM in
Entire Population
Cardiac
Biomarkers
Normal
(n  32)
CM
(n  10) p Value
Troponin T (g/l)
Baseline 0.01 0.01 1.00
3 months 0.01 0.01 1.00
6 months 0.01 0.01 1.00
9 months 0.01 0.01 1.00
12 months 0.01 0.01 1.00
CRP (mg/l)
Baseline 5.5 1.2 5.8 1.7 0.76
3 months 5.4 1.8 5.6 1.9 0.81
6 months 6.1 1.1 6.0 1.4 0.88
9 months 5.8 1.4 6.3 2.1 0.72
12 months 6.0 1.6 6.2 1.7 0.84
NT-proBNP (pmol/l)
Baseline 27.5 2.4 28.4 2.5 0.81
3 months 28.3 2.2 29.1 1.9 0.80
6 months 28.2 2.1 28.7 1.3 0.89
9 months 29.1 3.1 30.1 3.1 0.88
12 months 30.5 1.9 31.4 2.8 0.84
n  42. Values are mean  SD unless otherwise indicated.
CRP  C-reactive protein (normal reference: 8 mg/l); NT-proBNP  N-terminal pro-brain
atriuretic peptide (normal reference: 35 pmol/l); TnT  cardiac troponin T (normal reference:
0.01 g/l); other abbreviations as in Table 1.ere above this threshold (Table 4). The sensitivity, speci-
p
s
D
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respectively (Table 4). There were only 3 false positives in
the normal cohort (n 32). Similarly, the peak global radial
strain decreased from 41.4  10.5% at baseline to 34.5 
15.2% at 3 months in the CM group and continued to
decline up to 9 months (Table 3). With a cutoff value of
0.80% (difference between baseline and 3-month values for
peak radial strain), 9 of 10 CM patients were above this
Echocardiographic Parameters of Patients Withand Without Trastuzumab-Mediated CM intire Pop lation
Table 3
Echo ardiographic Param ters of Patients With
and Without Trastuzumab-Mediated CM in
Entire Population
Echocardiographic Variables
Normal
(n  32)
CM
(n  10) p Value
LV dimensions
LVEF
Baseline 62 5 64 3 0.31
3 months 60 8 58 4 0.69
6 months 64 4 42 9*† 0.001
9 months 65 4 39 5*† 0.001
12 months 61 9 49 4*† 0.001
TDI parameters
Mean S= (cm/s)
Baseline 8.9 1.4 9.2 1.6 0.47
3 months 9.1 1.6 6.4 0.6*† 0.001
6 months 8.9 0.8 4.3 0.5*† 0.001
9 months 9.0 0.7 3.9 0.7*† 0.001
12 months 8.7 1.1 5.8 0.8*† 0.001
Mean e= (cm/s)
Baseline 8.2 1.1 8.1 1.4 0.63
3 months 8.1 1.0 8.0 0.8 0.72
6 months 8.3 0.8 8.1 0.6 0.28
9 months 8.4 0.9 8.3 0.4 0.41
12 months 8.5 1.2 8.2 1.4 0.19
Mean a= (cm/s)
Baseline 7.9 1.1 7.8 1.3 0.58
3 months 7.8 1.0 7.6 1.1 0.32
6 months 7.7 0.8 7.5 0.9 0.38
9 months 7.9 0.9 7.7 1.1 0.44
12 months 8.0 1.2 7.9 1.1 0.56
2D speckle tracking
Peak global longitudinal strain
Baseline 20.2 2.4 19.8 1.8 0.72
3 months 19.9 2.3 16.4 1.1*† 0.001
6 months 19.4 2.8 15.4 1.8*† 0.001
9 months 20.1 1.7 12.4 2.1*† 0.001
12 months 19.8 1.9 15.9 2.7*† 0.001
Peak global radial strain
Baseline 40.1 11.1 41.4 10.5 0.57
3 months 42.4 13.2 34.5 15.2*† 0.001
6 months 41.3 15.4 30.5 16.5*† 0.001
9 months 40.4 15.2 29.4 12.3*† 0.001
12 months 44.5 17.2 33.4 16.4*† 0.001
n  42. Values are mean  SD. *p  0.05 was considered significant, comparing normal
population versus cardiomyopathy (CM) at same time point with the Mann-Whitney U test. †p 
0.05 was considered significant versus baseline within each group with a repeated measures
analysis of variance and Dunnett’s test.
2D  2-dimensional; a=  late diastolic annular velocity of the lateral wall; e=  early diastolic
annular velocity of the lateral left ventricular wall; LV  left ventricle; LVEF  left ventricular
ejection fraction; S=  systolic annular velocity of the lateral left ventricular wall; TDI  tissue
Doppler imaging. Lthreshold (Table 4). The sensitivity, specificity, PPV, and
NPV were 86%, 81%, 60%, and 95%, respectively (Table 4).
There were only 3 false positives in the normal cohort (n 
32). The LVEF subsequently decreased 10% in the CM
group at 6 months and continued to decline up to 9 months
of follow-up.
The intraobserver intraclass coefficients for S= with TVI,
peak global longitudinal strain, and peak global radial strain
were 0.96 (CV 2.4%), 0.94 (CV 3.5%), and 0.91 (CV 3.2%),
respectively. The interobserver intraclass coefficients for S=
with TVI, peak global longitudinal strain, and peak global
radial strain were 0.92 (CV 4.2%), 0.90 (CV 5.2%), and
0.82 (CV 5.4%), respectively.
The LV volumes and LVEF were within normal limits at
baseline in both groups with cardiac MRI (Table 5). There
was no change in LVEF in the normal group over the
12-month follow-up (Table 5). As compared with the
normal group, LV end-diastolic volume, and LV end-
systolic volume, as assessed by cardiac MRI, increased in the
CM group at 12 months of follow-up with a decrease in the
LVEF from 66  5% to 47  4%. There was evidence of
subepicardial linear delayed enhancement in the lateral wall
of the LV in all 10 patients who developed trastuzumab-
induced cardiac dysfunction (Fig. 1). The average size of
LGE was 18  4% of LV mass in these patients. In the
remaining 32 patients who did not develop trastuzumab-
ROC Curve Analysis for TVI and Strain ImagingTable 4 ROC Curve Analysis for TVI and Strain Imaging
Echocardiographic
Variables
Cutoff
Value
Sensitivity
(95% CI) Specificity PPV NPV
S= (cm/s) 0.60 0.93 (0.59–0.99) 0.99 0.96 0.98
Longitudinal strain 2.00 0.79 (0.51–0.96) 0.82 0.60 0.92
Radial strain 0.80 0.86 (0.57–0.98) 0.81 0.60 0.95
The cutoff values with the difference of baseline and 3-month measurements for the systolic
annular velocity of the lateral left ventricular wall (S=), longitudinal strain, and radial strain. The
sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) are
shown for each respective echocardiographic parameter.
CI  confidence interval; ROC  receiver-operator characteristic; TVI  tissue velocity imaging.
Cardiac MRI Parameters of Patients With andWithout Trastuzumab-Mediated CM in Entire PopulationTable 5 Cardiac MRI P ram ters of Patients With andWithout Trastuzumab-Mediated CM in Entire Population
CMR Variables,
LV Dimensions
Normal
(n  32)
CM
(n  10) p Value
LVEDV (ml)
Baseline 155 22 161 19 0.78
12 months 161 21 190 23*† 0.05
LVESV (ml)
Baseline 55 10 58 12 0.71
12 months 58 14 98 18*† 0.05
LVEF
Baseline 65 3 66 5 0.89
12 months 63 5 47 4*† 0.05
n  42. Values are mean  SD. *p  0.05 was considered significant comparing normal
opulation versus CM at same time point with the Mann-Whitney U test. †p 0.05 was considered
ignificant versus baseline within each group with a repeated measures analysis of variance and
unnett’s test.
CMR  cardiac magnetic resonance imaging; LVEDV  left ventricular end-diastolic volume;
VESV  left ventricular end-systolic volume; other abbreviations as in Tables 1 and 3.
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ment of the LV on cardiac MRI.
Discussion
Despite the clear therapeutic benefits of trastuzumab in
reducing breast cancer disease and recurrence in the adju-
vant setting, increased cardiotoxicity is a major concern,
especially when used in combination with anthracyclines.
The current study provides valuable insight into the use of
noninvasive imaging in the early detection of trastuzumab-
induced CM in the clinical setting of breast cancer. Al-
though cardiac biomarkers did not predict the development
of cardiac dysfunction, both TVI and strain imaging were
able to detect pre-clinical changes in LV systolic function,
before conventional changes in LVEF. Cardiac MRI demon-
strated changes in LV volumes and LVEF with characteristic
delayed enhancement findings observed in trastuzumab-
mediated CM.
Identifying women at risk of developing trastuzumab-
induced cardiac dysfunction continues to be an ongoing
challenge. In recent years, plasma biomarkers have been
extensively evaluated for early prediction of increased mor-
bidity and mortality in the clinical setting of heart failure
(12–14). Specifically, increased levels of TnT, CRP, and
BNP have been detected in a number of studies evaluating
LV systolic dysfunction due to chronic anthracycline treat-
ment (15,16). Although subclinical activation of cardiac
biomarkers might occur in anthracycline-mediated CM
(15,16), our study did not demonstrate any significant
Figure 1 Delayed Enhancement Cardiac Magnetic Resonance
Imaging in Trastuzumab-Mediated Cardiotoxicity
Short-axis phase sensitive reconstructed inversion recovery–true fast imaging
with steady-state precession image through the mid-ventricle at the level of the
papillary muscles, demonstrating midmyocardial delayed enhancement
(arrows) in the lateral wall of a patient who developed trastuzumab-mediated
cardiotoxicity.changes over 1 year of follow-up. The small number ofpatients (n  10) who developed trastuzumab-induced
cardiac dysfunction in the current study might account for
the lack of power for detecting a significant change in
biomarker levels.
As compared with cardiac biomarkers, echocardiography
with TVI and strain rate might be able to detect pre-clinical
changes in LV systolic function. Tissue velocity imaging—a
modification of conventional blood-flow Doppler that im-
ages tissue-derived, high-amplitude, and low-velocity
Doppler signals—is able to detect subtle, early changes in
LV systolic dysfunction before a decrease in conventional
LVEF parameters (17). Although recent animal studies
have demonstrated the utility of TVI for the early detection
of anthracycline mediated cardiac dysfunction (18), we
recently validated its potential application for the early
detection of trastuzumab-induced cardiotoxicity (19). We
demonstrated that TVI results were abnormal in mice
receiving either doxorubicin or trastuzumab  doxorubicin
as early as 24 h after treatment and were predictive of
ensuing LV systolic dysfunction and increased mortality
(19). Although TVI changed acutely on day 1, LVEF values
did not decrease until day 3 of the study (19). Whether TVI
and strain rate can detect subtle alterations in trastuzumab-
induced CM in the clinical setting, however, required
further study.
Recently, 2 clinical studies have evaluated the utility of
myocardial deformation in the pre-clinical detection of
trastuzumab-mediated cardiac dysfunction. Hare et al. (20)
evaluated a total of 35 breast cancer patients who received
trastuzumab in the adjuvant (n  27) and metastatic setting
(n  8). Although TVI (S=) was not specifically evaluated,
18 patients demonstrated a reduction in global longitudinal
strain rate at 3 months after trastuzumab treatment (20).
Three of 18 patients had concurrent drop in LVEF assess-
ment, and 2 additional patients demonstrated a future
decrease in LVEF within 20 months of follow-up (20).
Although there was no change in serial assessment of radial
or longitudinal strain in their study, there was a trend in
decreasing values that might have been detected with either
longer follow-up or a larger cohort of patients developing
trastuzumab-induced CM (20). Similarly, Ho et al. (21)
evaluated 19 breast cancer patients who received doxorubi-
cin followed by adjuvant trastuzumab therapy. In this small
study, there was no difference in TVI or strain parameters
comparing trastuzumab-treated patients with control sub-
jects (21). Although the study by Hare et al. (20) suggested
that strain rate might be able to predict LV systolic
dysfunction in breast cancer patients receiving trastuzumab
in the adjuvant setting, the small number of patients in the
study by Ho et al. (21) was not powered to detect mean-
ingful changes in parameters of myocardial deformation.
In our study, TVI and strain parameters did allow for the
early detection of subclinical cardiac dysfunction before
conventional echocardiographic parameters in breast cancer
patients receiving trastuzumab in the adjuvant setting.
Although there was no difference in conventional LVEF at
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TVI (S=) and strain decreased in all 10 patients who
developed cardiotoxicity. As compared with both global
longitudinal and radial strain, only S= was able to identify all
10 patients who developed trastuzumab-mediated CM,
with no false positives in the normal cohort at 3 months.
The LVEF subsequently decreased at 6 months of
follow-up in all 10 patients, necessitating discontinuation of
the drug. Although reduced diastolic parameters including
e= have been shown to be early predictors of developing
hypertrophic CM (27), we did not find a similar pattern in
trastuzumab-mediated CM, likely due to absence of signif-
icant LV hypertrophy in our patient population. As com-
pared with the previous clinical studies, our patient popu-
lation of 42 breast cancer patients receiving adjuvant therapy
with trastuzumab is the largest to date for assessing mean-
ingful changes in TVI and strain for the early prediction of
LV systolic dysfunction. Additionally, we evaluated S= with
VI and global longitudinal and radial strain with
-dimensional speckle tracking, allowing for a comprehen-
ive approach for assessing myocardial deformation in this
elect patient population.
As compared with echocardiography, cardiac MRI is the
old standard for the accurate determination of LV volumes
nd LVEF. Although cardiac MRI has been validated for
erial monitoring of LVEF in breast cancer patients receiv-
ng adjuvant therapy with trastuzumab (22,23), its high cost
nd low availability precludes its utility on a routine clinical
asis. Nonetheless, this is the first comprehensive study to
valuate cardiac biomarkers, echocardiography, and cardiac
RI in the early detection of trastuzumab-mediated car-
iotoxicity. We demonstrated that, in patients who devel-
ped a CM, the LV cavity volumes were increased with a
ubsequent decrease in LVEF at 12 months of follow-up.
inally, all 10 patients demonstrated delayed enhancement
f the lateral wall of the LV within the mid-myocardium
ortion, a common feature in breast cancer patients with
rastuzumab-induced CM (22,23).
tudy limitations. Although 10 of 42 patients demon-
trated early changes in TVI and strain parameters on TTE,
he number of patients who developed trastuzumab-
ediated cardiac dysfunction was small. A larger population
ith longer follow-up would be necessary to substantiate
hese findings. Additionally, whether delayed enhancement
ardiac MRI and/or T2 sequences for myocardial edema
ould be useful as an early predictor of ensuing LV systolic
ysfunction requires further study in this patient population.
onclusions
arly detection of trastuzumab-mediated cardiotoxicity
ith noninvasive imaging, in particular TVI and strain,
ight allow one to adjust treatment and/or the prophylactic
dministration of cardioprotective agents, before the devel-
pment of irreversible cardiac dysfunction.Acknowledgment
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